title: Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis.
abstract: The antituberculosis drug isoniazid (INH) is quickly oxidized by stoichiometric amounts of manganese(III) pyrophosphate. In the presence of nicotinamide coenzymes (NAD+, NADH, nicotinamide mononucleotide [NMN+]) and nicotinic acid adenine dinucleotide (DNAD+), INH oxidation produced the formation of INH-coenzyme adducts in addition to known biologically inactive products (isonicotinic acid, isonicotinamide, and isonicotinaldehyde). A pool of INH-NAD(H) adducts preformed in solution allowed the rapid and strong inhibition of in vitro activity of the enoyl-acyl carrier protein reductase InhA, an INH target in the biosynthetic pathway of mycolic acids: the inhibition was 90 or 60% when the adducts were formed in the presence of NAD+ or NADH, respectively. Under similar conditions, no inhibitory activity of INH-NMN(H) and INH-DNAD(H) adducts was detected. When an isolated pool of 100 nM INH-NAD(H) adducts was first incubated with InhA, the enzyme activity was inhibited by 80%; when present in excess, both NADH and decenoyl-coenzyme A are able to prevent this phenomenon. InhA inhibition by several types of INH-coenzyme adducts coexisting in solution is discussed in relation with the structure of the coenzyme, the stereochemistry of the adducts, and their existence as both open and cyclic forms. Thus, manganese(III) pyrophosphate appears to be an efficient and convenient alternative oxidant to mimic the activity of the Mycobacterium tuberculosis KatG catalase-peroxidase and will be useful for further mechanistic studies of INH activation and for structural investigations of reactive INH species in order to promote the design of new inhibitors of InhA as potential antituberculous drugs.
authors.affiliation: Laboratoire de Chimie de Coordination du CNRS, 31077 Toulouse Cedex, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Nguyen
authors.forename: Annaïk
authors.initials: A
authors.lastname: Quémard
authors.forename: Sylvain
authors.initials: S
authors.lastname: Broussy
authors.forename: Jean
authors.initials: J
authors.lastname: Bernadou
authors.forename: Bernard
authors.initials: B
authors.lastname: Meunier
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D001426:Bacterial Proteins; D001711:Biotransformation; D011756:Diphosphates / Q000494:pharmacology*; D007538:Isoniazid / Q000378:metabolism / Q000494:pharmacology*; D008345:Manganese / Q000494:pharmacology*; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D009243:NAD / Q000378:metabolism; D010084:Oxidation-Reduction; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*
chemical_list: D000995:Antitubercular Agents; D001426:Bacterial Proteins; D011756:Diphosphates; D009243:NAD; D008345:Manganese; D010088:Oxidoreductases; C085257:InhA protein, Mycobacterium; D007538:Isoniazid